Healthcare >> CEO Interviews >> February 24, 1999
TIMOTHY R. SURGENOR is President, Chief Executive Officer and Director
of Cyberkinetics Neurotechnology Systems, Inc. Mr. Surgenor joined
Cyberkinetics in 2003 from Haemonetics Corporation, a medical device
company located in Braintree, Massachusetts where he was Executive Vice
President with responsibility for business development, global
marketing, quality assurance and regulatory affairs from 1999 to 2003.
While at Haemonetics, Mr. Surgenor was an active member of the investor
relations effort. From 1994 to 1999, Mr. Surgenor was President of
Genzyme Tissue Repair, the cell therapy division of Genzyme Corporation,
located in Cambridge, Massachusetts. While at Genzyme Tissue Repair, Mr.
Surgenor led successful public offerings which raised approximately $100
million. Previously, Mr. Surgenor was Executive Vice President and Chief
Financial Officer of BioSurface Technology, Inc., and also held various
positions in operations at Integrated Genetics. Mr. Surgenor received a
BA in Biochemistry from Williams College in 1981 and an MBA from Harvard
Business School in 1987. Profile
significant trends that may occur over the next couple of years?
Mr. Surgenor: Strategically, the major focus for us is the
